CTNM Key Statistics, Chart & Performance
The current stock price of CTNM is 10.71 USD. In the past month the price decreased by -2.9%. In the past year, price decreased by -28.17%.
CTNM Latest News, Press Relases and Analysis
CTNM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.47 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.91 | 497.73B | ||
| MRK | MERCK & CO. INC. | 11.99 | 263.92B | ||
| PFE | PFIZER INC | 8.04 | 146.23B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.48 | 99.84B | ||
| ZTS | ZOETIS INC | 20.17 | 56.68B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 23.06B | ||
| VTRS | VIATRIS INC | 4.53 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.41 | 11.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.23 | 8.44B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.46B |
Related stock screener links
About CTNM
Company Profile
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Company Info
CONTINEUM THERAPEUTICS INC-A
3565 General Atomics Court, Suite 200
San Diego CALIFORNIA US
Employees: 41
Phone: 18583335280
CONTINEUM THERAPEUTICS INC-A / CTNM FAQ
What does CONTINEUM THERAPEUTICS INC-A do?
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Can you provide the latest stock price for CONTINEUM THERAPEUTICS INC-A?
The current stock price of CTNM is 10.71 USD. The price increased by 3.38% in the last trading session.
What is the dividend status of CONTINEUM THERAPEUTICS INC-A?
CTNM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTNM stock?
CTNM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CTNM stock?
13 analysts have analysed CTNM and the average price target is 23.8 USD. This implies a price increase of 122.22% is expected in the next year compared to the current price of 10.71.
Can you provide the upcoming earnings date for CONTINEUM THERAPEUTICS INC-A?
CONTINEUM THERAPEUTICS INC-A (CTNM) will report earnings on 2026-03-04, after the market close.
CTNM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CTNM. When comparing the yearly performance of all stocks, CTNM is a bad performer in the overall market: 77.64% of all stocks are doing better.
CTNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTNM. CTNM has a great financial health rating, but its profitability evaluates not so good.
CTNM Financial Highlights
Over the last trailing twelve months CTNM reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS decreased by -341.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.85% | ||
| ROE | -21.34% | ||
| Debt/Equity | 0 |
CTNM Forecast & Estimates
13 analysts have analysed CTNM and the average price target is 23.8 USD. This implies a price increase of 122.22% is expected in the next year compared to the current price of 10.71.